InProTher is a biotechnology company developing ground-breaking immunotherapies to fight and treat cancer. In late 2021, Innovayt helped InProTher secure €9.1 million from the EIC Accelerator programme, which allows them to fully develop their technology and bring the first broad cancer vaccine to market.
Secured in total €2.7 million in grant from the MSCA Doctoral Network programme to implement the BiodeCCodiNNg project, with the main goal to train 10 Ph.D. students with out-of-the-box thinking and an entrepreneurial mindset to expand the repertoire of enzymes for industrial biotechnology.
CardiNor AS holds exclusive rights to secretoneurin, a breakthrough blood biomarker for cardiovascular disease. Secured 1.15M EUR in grant from the IPN funding programme to continue researching and developing both the usage and testing of secretoneurin.
Bulbitech strives to introduce a paradigm shift in neuro-ophthalmic care by developing an automated and digitised diagnostic support device for early detection of neuro-ophthalmic diseases. Secured 14.175M NOK in grant from the IPN funding programme to expand the eye examination tests available.
Pioneering stem cell treatment for chronic diseases, using Blue Cells to reverse Erectile Dysfunction. Secured EUROSTARS and InnoBooster grants to develop autologous and allogeneic treatments, respectively.
Ground-breaking technology to bond dissimilar materials based on specifically designed polymer brushes.
Funding from the Research Council of Norway to support preclinical trials of new chemotherapeutic agents.